未找到相关数据
Final analysis COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel(D) and abiraterone (A) and/or enzalutamide (E)
被引：21
作者：
Basch, Ethan M.
Sholz, Mark C.
De Bono, Johann Sebastian
Vogelzang, Nicholas J.
De Souza, Paul L.
Marx, Gavin M.
Vaishampayan, Ulka N.
George, Saby
Schwarz, James K.
Antonarakis, Emmanuel S.
O'Sullivan, Joe M.
Kelabasty, Arash Rezazadeh
Chi, Kim N.
Dreicer, Robert
Hutson, Thomas E.
Mangeshkar, Milan
Holland, Jaymoe S.
Weitzman, Aaron
Scher, Howard I.
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Prostate Oncol Specialists, Marina Del Rey, CA USA
[3] Royal Marsden Hosp NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England
[4] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[5] St George Private Hosp, Sydney, NSW, Australia
[6] Sydney Adventist Hosp, Sydney, NSW, Australia
[7] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[8] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[9] Univ Nebraska Med Ctr, Omaha, NE USA
[10] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[11] Belfast City Hosp, Belfast BT9 7AD, Antrim, North Ireland
[12] Norton Canc Inst Pavil, Louisville, KY USA
[13] Vancouver Canc Ctr, BC Canc Agcy, Vancouver, BC, Canada
[14] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
[15] Texas Oncol Sammons Canc Ctr, Dallas, TX USA
[16] Exelixis Inc, San Francisco, CA USA
[17] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
141
引用
收藏
页数：1
相关论文